Literature DB >> 6093054

Reversion to neurovirulence of the live-attenuated Sabin type 3 oral poliovirus vaccine.

A J Cann, G Stanway, P J Hughes, P D Minor, D M Evans, G C Schild, J W Almond.   

Abstract

The complete nucleotide sequence has been determined of a strain of poliovirus type 3, P3/119, isolated from the central nervous system of a victim of fatal vaccine-associated poliomyelitis. Comparison of this sequence with those obtained previously for the Sabin type 3 vaccine, P3/Leon 12a1b and its neurovirulent progenitor, P3/Leon/37, reveals that these three strains are on a direct geneaological lineage and therefore that P3/119 is a bona fide revertant of the vaccine. P3/119 differs in sequence from its attenuated vaccine parent at just seven positions. Only one of these differences, a mutation from U to C at position 472 in the presumed noncoding region of the genome, is a back mutation to the wild type sequence. Of the six other differences, three give rise to coding changes in virus structural proteins, two are silent changes in the major open reading frame of the genome and one affects the 3'-terminus just prior to the poly A tract. These differences indicate that there are three possible types of molecular change which could, singly or collectively, result in attenuation and reversion to neurovirulence of the Sabin type 3 vaccine.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6093054      PMCID: PMC320200          DOI: 10.1093/nar/12.20.7787

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  16 in total

1.  Molecular cloning of poliovirus cDNA and determination of the complete nucleotide sequence of the viral genome.

Authors:  V R Racaniello; D Baltimore
Journal:  Proc Natl Acad Sci U S A       Date:  1981-08       Impact factor: 11.205

2.  Cloned poliovirus complementary DNA is infectious in mammalian cells.

Authors:  V R Racaniello; D Baltimore
Journal:  Science       Date:  1981-11-20       Impact factor: 47.728

3.  Primary structure, gene organization and polypeptide expression of poliovirus RNA.

Authors:  N Kitamura; B L Semler; P G Rothberg; G R Larsen; C J Adler; A J Dorner; E A Emini; R Hanecak; J J Lee; S van der Werf; C W Anderson; E Wimmer
Journal:  Nature       Date:  1981-06-18       Impact factor: 49.962

4.  Characterization of strains of type 3 poliovirus by oligonucleotide mapping.

Authors:  P D Minor
Journal:  J Gen Virol       Date:  1982-04       Impact factor: 3.891

Review 5.  Control of poliomyelitis: a continuing paradox.

Authors:  D M Horstmann
Journal:  J Infect Dis       Date:  1982-10       Impact factor: 5.226

6.  Buffer gradient gels and 35S label as an aid to rapid DNA sequence determination.

Authors:  M D Biggin; T J Gibson; G F Hong
Journal:  Proc Natl Acad Sci U S A       Date:  1983-07       Impact factor: 11.205

7.  Poliovirus type 3: molecular cloning of the genome and nucleotide sequence of the region encoding the protease and polymerase proteins.

Authors:  A J Cann; G Stanway; R Hauptmann; P D Minor; G C Schild; L D Clarke; R C Mountford; J W Almond
Journal:  Nucleic Acids Res       Date:  1983-03-11       Impact factor: 16.971

8.  Evolution of poliovirus since introduction of attenuated vaccine.

Authors:  Y E Cossart
Journal:  Br Med J       Date:  1977-06-25

9.  DNA sequencing with chain-terminating inhibitors.

Authors:  F Sanger; S Nicklen; A R Coulson
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

Review 10.  Paralytic poliomyelitis: Old dogmas and new perspectives.

Authors:  A B Sabin
Journal:  Rev Infect Dis       Date:  1981 May-Jun
View more
  47 in total

Review 1.  Vaccine and adjuvant design for emerging viruses: mutations, deletions, segments and signaling.

Authors:  Gavin C Bowick; Alexander J McAuley
Journal:  Bioeng Bugs       Date:  2011-05-01

2.  Massively parallel sequencing for monitoring genetic consistency and quality control of live viral vaccines.

Authors:  Alexander Neverov; Konstantin Chumakov
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-01       Impact factor: 11.205

3.  An assembly defect as a result of an attenuating mutation in the capsid proteins of the poliovirus type 3 vaccine strain.

Authors:  A J Macadam; G Ferguson; C Arnold; P D Minor
Journal:  J Virol       Date:  1991-10       Impact factor: 5.103

4.  Identification of a consistent pattern of mutations in neurovirulent variants derived from the sabin vaccine strain of poliovirus type 2.

Authors:  M Equestre; D Genovese; F Cavalieri; L Fiore; R Santoro; R Perez Bercoff
Journal:  J Virol       Date:  1991-05       Impact factor: 5.103

5.  An enhanced promoter trap protocol.

Authors:  A Toyoda; J Kusuda; H Maeda; K Hashimoto
Journal:  Mamm Genome       Date:  1995-06       Impact factor: 2.957

6.  Mapping of mutations associated with neurovirulence in monkeys infected with Sabin 1 poliovirus revertants selected at high temperature.

Authors:  C Christodoulou; F Colbere-Garapin; A Macadam; L F Taffs; S Marsden; P Minor; F Horaud
Journal:  J Virol       Date:  1990-10       Impact factor: 5.103

Review 7.  Molecular typing of enteroviruses: current status and future requirements. The European Union Concerted Action on Virus Meningitis and Encephalitis.

Authors:  P Muir; U Kämmerer; K Korn; M N Mulders; T Pöyry; B Weissbrich; R Kandolf; G M Cleator; A M van Loon
Journal:  Clin Microbiol Rev       Date:  1998-01       Impact factor: 26.132

8.  Identification of two determinants that attenuate vaccine-related type 2 poliovirus.

Authors:  R B Ren; E G Moss; V R Racaniello
Journal:  J Virol       Date:  1991-03       Impact factor: 5.103

Review 9.  Comparative pathogenesis and systems biology for biodefense virus vaccine development.

Authors:  Gavin C Bowick; Alan D T Barrett
Journal:  J Biomed Biotechnol       Date:  2010-06-06

10.  Characterisation of a GII-4 norovirus variant-specific surface-exposed site involved in antibody binding.

Authors:  David J Allen; Rob Noad; Dhan Samuel; Jim J Gray; Polly Roy; Miren Iturriza-Gómara
Journal:  Virol J       Date:  2009-09-25       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.